Profile data is unavailable for this security.
About the company
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
- Revenue in USD (TTM)0.00
- Net income in USD-66.03m
- Incorporated2017
- Employees41.00
- LocationAN2 Therapeutics Inc1800 El Camino Real, Suite DMENLO PARK 94025-3069United StatesUSA
- Phone+1 (650) 331-9090
- Websitehttps://www.an2therapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnstone Biologics Corp | 0.00 | -74.92m | 62.45m | 82.00 | -- | 0.7805 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
RetinalGenix Technologies Inc | 0.00 | -3.73m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2124 | -0.2124 | 0.00 | -0.085 | 0.00 | -- | -- | -- | -12,800.17 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -969.35 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
vTv Therapeutics Inc | 1.00m | -20.62m | 63.27m | 16.00 | -- | 3.04 | -- | 63.27 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -22.12m | 63.58m | 31.00 | -- | 1.50 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Rallybio Corp | 0.00 | -76.28m | 64.04m | 43.00 | -- | 0.6552 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Avrobio Inc | 0.00 | 30.31m | 64.20m | 13.00 | 2.07 | 0.7224 | 2.10 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Tempest Therapeutics Inc | 0.00 | -29.76m | 64.43m | 17.00 | -- | 3.12 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Passage Bio Inc | 0.00 | -84.44m | 64.72m | 58.00 | -- | 0.6168 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
AN2 Therapeutics Inc | 0.00 | -66.03m | 64.73m | 41.00 | -- | 0.585 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Kronos Bio Inc | 7.59m | -116.39m | 64.90m | 61.00 | -- | 0.4738 | -- | 8.55 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
Medicinova Inc | 1.00m | -8.41m | 65.23m | 13.00 | -- | 1.09 | -- | 65.23 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Annovis Bio Inc | 0.00 | -47.53m | 65.35m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Cue Biopharma Inc | 7.02m | -49.97m | 66.15m | 53.00 | -- | 2.20 | -- | 9.42 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 66.70m | 4.00 | -- | -- | -- | 112.91 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Intensity Therapeutics Inc | 0.00 | -15.13m | 66.78m | 5.00 | -- | 6.87 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Mar 2024 | 5.55m | 18.61% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.56m | 5.22% |
BVF Partners LPas of 31 Mar 2024 | 1.24m | 4.16% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.22m | 4.09% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.15m | 3.86% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 1.10m | 3.70% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.04m | 3.49% |
Adage Capital Management LPas of 31 Mar 2024 | 312.62k | 1.05% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 283.60k | 0.95% |
Ghost Tree Capital LLCas of 31 Mar 2024 | 219.33k | 0.74% |